← Leaderboards
Nicolas L'heureux
Cytograft Tissue Engineering, Inc.
$5,243,423
Attributed
$5,243,423
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $901.8K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$5,243,423 · 4
By mechanism
R44$4,813,096 · 2
R43$430,327 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsTissue EngineeringBiologicalMechanicsBaseTissuesIn VivoGrantCellsAnimalsCaliberVascular GraftProductionCanis FamiliarisPropertyAutologousFailure (Biologic Function)DesignManufacturing ProcessSerumCattleCollagenAnimal ModelAffect
Grant awards (9)
Cell-synthesized Thread-based Tissue Engineering$705,170
R44 · FY2012 · HL · contact PI
Cell-synthesized Thread-based Tissue Engineering$768,475
R44 · FY2011 · HL · contact PI
Cell-synthesized Thread-based Tissue Engineering$215,415
R43 · FY2010 · HL · contact PI
Development of a Biological Stent Graft for Aorta Aneurysm Repair$214,912
R43 · FY2010 · HL · contact PI
Commercialization of a Tissue Engineered Blood Vessel$728,532
R44 · FY2007 · HL · contact PI
Commercialization of a Tissue Engineered Blood Vessel$901,757
R44 · FY2006 · HL · contact PI
Commercialization of a Tissue Engineered Blood Vessel$851,862
R44 · FY2005 · HL
in vivo Evaluation of a Tissue Blood Vessel$427,550
R44 · FY2004 · HL
in vivo Evaluation of a Tissue Blood Vessel$429,750
R44 · FY2003 · HL